Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients Treated With Teriflunomide and Alemtuzumab
Clinical trial NCT05075499 · UNKNOWN
Trial details
- NCT number
- NCT05075499
- Sponsor
- Sheba Medical Center
- Status
- UNKNOWN
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-20
- Primary completion
- 2021-12-01
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.